R

Roivant Sciences Ltd
D

ROIV

12.520
USD
0.69
(5.83%)
Market Closed
Volume
391,827
EPS
-1
Div Yield
-
P/E
2
Market Cap
9,113,930,795
News

Title: Roivant Sciences Ltd

Sector: Healthcare
Industry: Biotechnology
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.